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Vrolix M, Legrand V, Vrints C, Vanoverschelde JL, Crespo-Diaz R, Homsy C, Tendera M, Waldman S, Wijns W,
Terzic A. Cardiopoietic Stem Cell Therapy in Heart Failure: The C-CURE (Cardiopoietic stem Cell therapy in heart
failURE) Multicenter Randomized Trial With Lineage-Speciﬁed Biologics. J Am Coll Cardiol 2013;61:2329–38.
There was an imprecision in the text (page 2330) where 48 patients who entered the consent process are described
as ‘randomized’. It would have been more precise to state, “Consent was requested from 48 patients, and 47 were
randomized.”.
We here include an updated demographics Table 1 with baseline characteristics pertinent to both analysis as intention to treat
and with all patients not receiving cells as controls. Neither the 15/21 nor the 24/21 baseline comparisons reveal signiﬁcant
differences in populations, nor change the outcome of efﬁcacy signals. The revised table corrects for original typographical
errors, which had no material impact on trial ﬁndings, interpretations or conclusions An updated Table 1 also provides an
additional breakdown of control patients. The table also corrects for 2 elements: one related to statistical misprogramming
of the SAS data, and a typographical mistake whereby patients under Statins should be 23 (96%) instead of 13 (96%).Table 1
Patient Demographics, Cardiac History, and Medication Proﬁle in Control and
Cell Therapy Cohorts
Control
(N ¼ 15)
Control
(N ¼ 24)
Cell Therapy
(N ¼ 21)
p Value
15/21
p Value
24/21
Age, yrs 58.7  8.2 59.5  8.0 55.3  10.4 0.424 0.234
Sex, M/F 13/2 22/2 19/2 0.720 0.889
Family history, CAD 9 (64)* 12 (52)* 15 (71) 0.657 0.19
Smoking
Former 9 (60) 18 (75) 11 (52) 0.650 0.114
Current 5 (33) 5 (21) 5 (24) 0.529 0.811
Arterial hypertension 7 (47) 13 (54) 9 (43) 0.820 0.450
Diabetes mellitus 4 (27) 8 (33) 4 (19) 0.588 0.280
on diet 1 (7) 3 (13) 1 (5) 0.806 0.363
NIDDM 1 (7) 2 (8) 2 (10) 0.760 0.889
IDDM 2 (13) 3 (13) 1 (5) 0.359 0.363
Hypercholesterolemia 15 (100) 24 (100) 16 (76) 0.042 0.011
On diet 1 (7) 1 (4) 0 (0) 0.230 0.344
On statins 14 (93) 23 (96) 16 (76) 0.174 0.053
Cardiac history
ICD implant 3 (20) 8 (33) 10 (48) 0.089 0.329
CRT implant 1 (7) 2 (8) 1 (5) 0.801 0.632
PCI 14 (93) 21 (88) 17 (81) 0.290 0.545
CABG 3 (20) 8 (33) 4 (19) 0.943 0.280
MI 15 (100) 23 (96) 21 (100) N/A 0.344
Other cardiac surgery 1 (7) 2 (8) 2 (10) 0.760 0.889
Sustained VT or VF 5 (33) 9 (38) 4 (19) 0.329 0.173
Atrial ﬁbrillation 2 (13) 3 (13) 4 (19) 0.650 0.545
Medication proﬁle
ACE inhibitor 13 (87) 19 (79) 18 (86) 0.935 0.567
ATR1-blocker 2 (13) 4 (17) 3 (14) 0.935 0.826
Beta-blocker 11 (73) 19 (79) 20 (95) 0.061 0.114
Diuretic agent 13 (87) 19 (79) 18 (86) 0.935 0.567
Antiplatelet agent 15 (100) 23 (96) 20 (86) 0.391 0.923
Statins 14 (93) 23 (96) 17 (81) 0.290 0.113
Hypoglycemic agent 2 (13) 4 (17) 2 (10) 0.720 0.482
Antiarrhythmic agent 2 (13) 4 (17) 9 (43) 0.058 0.531
Calcium antagonist 1 (7) 1 (4) 3 (14) 0.473 0.234
Nitrate or molsidomine 5 (33) 7 (29) 2 (10) 0.075 0.100
*Family history of CAD of one control was not available.
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2458A typographical error was noted in Table 2 where the number of patients in the treatment group (Post Cell Rx) of 6 is given
a percentage of 20 which should read 28. There are also three rounding errors with 2 of 24 patients (8.33%) rounded to 8.4%,
2 of 24 patients (12.5%) given as (12.6%) and 2 of 21 patients (9.52%) rounded to 9.6%.
In Figure 5C and the Online Appendix, mortality and hospitalization data are at 2 years as described in the Methods. This
should have been made clear in respective legends to be consistent with main text (page 2334). Values are accurate in the
paper’s ﬁgures and in main text.
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